Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
Genderless Sterile Connectors: How They Can Increase Efficiency, Saving You Time and Money
Todd Andrews
August 10, 2016
1 Min Read
Sponsored by Colder Products Company
Standardizing equipment in biopharmaceutical production streamlines operations, saving end users time and money. An area ripe for standardization is the use of genderless connections, those in which the connector halves are identical in design. Historically, single-use connections have involved male and female halves, but using two different parts can create several inefficiencies and complications, such as
Increased ordering complexity
Greater risk of specifying the wrong system or connection, resulting in downtime and last-minute adjustments
Longer lead times
Increased stocking requirements
By standardizing single-use genderless connectors, end users can accomplish more with fewer finished goods, save time, reduce overhead costs, and get their biopharmaceutical products to market more efficiently. Benefits include
Streamlined operations with easy to use, robust sterile connections
More flexibility and decreased bottlenecks with on-site connector assembly
Reduced overhead costs, freeing up capital for other projects.
Overall, genderless connector standardization will help bioprocessing facilities simplify their operations and implement single-use technology to its full potential.
Todd Andrews is the global sales and business development manager, Bioprocessing at CPC, 1001 Westgate Drive, St. Paul, MN 55114; 1-651645-0091; [email protected].
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More